Amardeep S Aulakh, DO
Internal Medicine · Fresno
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
- Since medical school
- 18 years
- Graduated 2008
Offices
3 locations · California Cancer Associates for Research and Excellence Inc · 64 clinicians in this group
Looking this up.
Hospitals listed: Saint Agnes Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Aulakh’s office to ask if they take your plan before you enroll.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Saint Agnes Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.312, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.141, Oct 2024 – Sep 2025
See every measure and the patient survey for Saint Agnes Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.312 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.141 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.18 to 1.94) · 2,342 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 197.82 (152.64 to 243.01) · 103 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 300 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 768 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.8 · 969 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 304 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 4,305 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.06 to 0.42) · 11,641 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.07 to 0.43) · 12,213 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.76 (2.91 to 6.61) · 2,466 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.09 (0 to 2.49) · 864 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.61 (0.26 to 2.96) · 2,362 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.1 (5.39 to 14.81) · 900 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.4 (1.2 to 7.59) · 882 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.84 (0.41 to 3.27) · 541 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.67 (0.14 to 1.19) · 9,626 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 58 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.835 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.182 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.004 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 412 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.6 · 1,002 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 28.8 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.5 · 894 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.8 · 981 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 1,061 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 13.4 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 412 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.6 to 15.9) · 1,324 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 863 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 32% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$6,511,514
Medicare paid this office $6,511,514 for 1,119 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, nivolumab, 1 mg | 37 | $726,852 | None |
| Injection, pembrolizumab, 1 mg | 16 | $573,071 | None |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 27 | $303,153 | None |
| Injection, durvalumab, 10 mg | 13 | $279,688 | None |
| Injection, denosumab, 1 mg | 94 | $275,698 | None |
See all 90 services
| Injection, nivolumab, 1 mg | 37 | $726,852 | None |
| Injection, pembrolizumab, 1 mg | 16 | $573,071 | None |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 27 | $303,153 | None |
| Injection, durvalumab, 10 mg | 13 | $279,688 | None |
| Injection, denosumab, 1 mg | 94 | $275,698 | None |
| Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg | 53 | $273,727 | $256 |
| Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | 20 | $236,718 | $52 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 106 | $205,229 | None |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 91 | $183,762 | $1,371 |
| Injection, ferric derisomaltose, 10 mg | 74 | $141,848 | None |
| Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | 11 | $90,747 | $32 |
| Return visit (30+ min) | 500 | $87,494 | $97 |
| Injection, paclitaxel protein-bound particles, 1 mg | 11 | $71,375 | None |
| Long return visit (40+ min) | 159 | $64,611 | $143 |
| Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie | 11 | $54,609 | $840 |
| Administration of chemotherapy into vein, 1 hour or less | 144 | $52,103 | $106 |
| Injection, ferric carboxymaltose, 1 mg | 42 | $42,829 | None |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 87 | $37,471 | $282 |
| Injection, granisetron, extended-release, 0.1 mg | 19 | $19,394 | None |
| New patient visit (60+ min) | 115 | $19,323 | $168 |
| Short return visit (20+ min) | 232 | $19,303 | $69 |
| Blood test, comprehensive group of blood chemicals | 575 | $18,932 | $10 |
| Insertion of needle into vein for collection of blood sample | 576 | $17,421 | $9 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 574 | $17,171 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 168 | $15,997 | $49 |
| Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | 63 | $14,795 | $48 |
| Injection, aprepitant, 1 mg | 31 | $14,764 | None |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 63 | $14,307 | $51 |
| Injection, palonosetron hydrochloride (avyxa), not therapeutically equivalent to j2469, 25 micrograms | 12 | $14,051 | None |
| Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg | 12 | $13,482 | None |
| Injection, triptorelin pamoate, 3.75 mg | 11 | $13,096 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 141 | $13,066 | $23 |
| Ct scan of abdomen and pelvis with contrast | 44 | $12,165 | $234 |
| Flow cytometry technique for dna or cell analysis, each additional marker | 25 | $12,034 | $19 |
| Injection of drug or substance under skin or into muscle | 381 | $11,903 | $11 |
| Administration of additional new drug or substance into vein, 1 hour or less | 54 | $9,880 | $53 |
| Ferritin (blood protein) level | 301 | $8,033 | $13 |
| Injection, alteplase recombinant, 1 mg | 25 | $7,454 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 12 | $7,125 | None |
| Electrophoresis, laboratory testing technique | 100 | $6,991 | $60 |
| Ct scan of chest with contrast | 48 | $5,744 | $103 |
| Telephone medical discussion with physician, 21-30 minutes | 51 | $5,635 | $102 |
| Carcinoembryonic antigen (cea) protein level | 130 | $5,593 | $19 |
| Iron binding capacity | 302 | $5,401 | $9 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 245 | $4,798 | $13 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $4,190 | $135 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 57 | $4,149 | $16 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 42 | $4,052 | $39 |
| Iron level | 302 | $3,996 | $6 |
| Cyanocobalamin (vitamin b-12) level | 209 | $3,610 | $15 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 31 | $3,389 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $3,347 | $93 |
| Administration of prolonged chemotherapy into vein | 15 | $3,324 | $107 |
| Administration of chemotherapy into vein, each additional hour | 43 | $3,045 | $22 |
| Ct scan of chest without contrast | 29 | $3,028 | $95 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 62 | $2,671 | $20 |
| Folic acid level, serum | 161 | $2,551 | $14 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 27 | $2,511 | $29 |
| Injection of additional new drug or substance into vein | 56 | $2,374 | $13 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 17 | $1,896 | $20 |
| Psa (prostate specific antigen) measurement, total | 30 | $1,784 | $18 |
| Flow cytometry technique for dna or cell analysis, first marker | 25 | $1,566 | $60 |
| Declotting of central venous tube | 24 | $1,543 | $29 |
| Injection, leucovorin calcium, per 50 mg | 15 | $1,427 | None |
| Gammaglobulin (immune system protein) measurement | 76 | $1,367 | $9 |
| Administration of additional new drug or substance into vein using push technique | 12 | $1,320 | $46 |
| Injection, carboplatin, 50 mg | 17 | $1,227 | None |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | 13 | $1,142 | $20 |
| Telephone medical discussion with physician, 11-20 minutes | 18 | $1,064 | $59 |
| Lactate dehydrogenase (enzyme) level | 97 | $989 | $6 |
| Injection, bortezomib, 0.1 mg | 15 | $980 | None |
| Injection, palonosetron hcl, 25 mcg | 35 | $905 | None |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 70 | $718 | $0 |
| Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month | 12 | $688 | $38 |
| Injection, fluorouracil, 500 mg | 16 | $664 | None |
| Haptoglobin (serum protein) level | 51 | $653 | $12 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 17 | $522 | $16 |
| Injection, oxaliplatin, 0.5 mg | 11 | $447 | None |
| Injection, paclitaxel, 1 mg | 15 | $386 | None |
| Red blood count, automated test | 79 | $313 | $4 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 99 | $303 | None |
| Injection, methylprednisolone sodium succinate, 5 mg | 19 | $274 | None |
| Urinalysis, manual test | 17 | $273 | $3 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 13 | $225 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 78 | $220 | None |
| Injection, testosterone cypionate, 1 mg | 12 | $198 | None |
| Blood test, clotting time | 12 | $189 | $4 |
| Injection, diphenhydramine hcl, up to 50 mg | 90 | $177 | None |
| Unclassified drugs | 75 | $131 | None |
| Injection, magnesium sulfate, per 500 mg | 13 | $61 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Declotting of central venous tube | – | – | – | 36 | 47 | 54 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
1,119 Original Medicare patients in 2024. Average age 74 · Under 65 8% · 85 and older 14% · Women 58% · Also on Medicaid 39% · Health risk score 2.09. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Diabetes 45% · Chronic kidney disease 44% · Cancer 39% · Coronary heart disease 38% · Heart failure 27% · COPD 21% · Atrial fibrillation 20% · Depression 20% · Dementia 7% · Stroke 7%.
The office billed $22,906,312, Medicare allowed $8,167,881 and paid $6,511,514; for 369,828 services of 205 kinds; $5,666,557 of it was for drugs given in the office and $844,957 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,119 | 369,828 | 74 | 2.09 | $22,906,312 | $6,511,514 |
| 2023 | 1,082 | 457,180 | 74 | 1.97 | $19,857,694 | $5,437,521 |
| 2022 | 981 | 429,825 | 74 | 1.86 | $18,042,701 | $4,764,404 |
| 2021 | 940 | 477,120 | 73 | 2.01 | $20,222,463 | $5,150,199 |
| 2020 | 919 | 431,049 | 73 | 2.20 | $17,845,034 | $4,952,682 |
| 2019 | 545 | 390,859 | 73 | 2.05 | $26,663,437 | $3,527,196 |
| 2018 | 494 | 209,174 | 73 | 2.23 | $17,411,597 | $2,137,660 |
| 2017 | 511 | 233,797 | 74 | 2.51 | $16,807,575 | $2,003,254 |
| 2016 | 439 | 165,630 | 73 | 2.32 | $13,463,278 | $1,637,073 |
| 2015 | 441 | 122,010 | 72 | 2.38 | $8,154,875 | $945,830 |
| 2014 | 72 | 9,786 | 70 | 1.81 | $371,923 | $36,539 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 81 services
| Injection, nivolumab, 1 mg | 24 | $565,876 | None |
| Injection, pembrolizumab, 1 mg | 17 | $542,884 | None |
| Injection, denosumab, 1 mg | 100 | $257,036 | None |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 30 | $253,873 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 110 | $207,557 | None |
| Injection, eflapegrastim-xnst, 0.1 mg | 27 | $200,153 | None |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 87 | $179,875 | $1,363 |
| Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | 13 | $155,953 | $57 |
| Injection, paclitaxel protein-bound particles, 1 mg | 13 | $141,329 | None |
| Injection, ferric carboxymaltose, 1 mg | 119 | $116,598 | None |
| Return visit (30+ min) | 529 | $105,103 | $100 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 14 | $98,514 | None |
| Unclassified biologics | 16 | $90,846 | None |
| Long return visit (40+ min) | 154 | $64,684 | $142 |
| Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg | 15 | $59,406 | $261 |
| Administration of chemotherapy into vein, 1 hour or less | 144 | $58,047 | $110 |
| Injection, ferric derisomaltose, 10 mg | 29 | $48,889 | None |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 92 | $39,330 | $285 |
| Injection, granisetron, extended-release, 0.1 mg | 17 | $28,205 | None |
| Short return visit (20+ min) | 169 | $21,396 | $67 |
| Blood test, comprehensive group of blood chemicals | 594 | $19,197 | $10 |
| Insertion of needle into vein for collection of blood sample | 614 | $18,221 | $8 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 600 | $18,026 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 189 | $17,894 | $53 |
| New patient visit (60+ min) | 106 | $17,447 | $165 |
| Injection, aprepitant, 1 mg | 26 | $15,178 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 133 | $14,977 | $24 |
| Ct scan of abdomen and pelvis with contrast | 40 | $12,692 | $264 |
| Injection of drug or substance under skin or into muscle | 377 | $12,193 | $11 |
| Administration of additional new drug or substance into vein, 1 hour or less | 48 | $10,270 | $55 |
| Ferritin (blood protein) level | 328 | $8,285 | $13 |
| Electrophoresis, laboratory testing technique | 111 | $7,356 | $60 |
| Flow cytometry technique for dna or cell analysis, each additional marker | 16 | $7,127 | $21 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $6,919 | $96 |
| Ct scan of chest with contrast | 49 | $6,565 | $104 |
| Carcinoembryonic antigen (cea) protein level | 136 | $6,397 | $19 |
| Injection, alteplase recombinant, 1 mg | 28 | $6,296 | None |
| Iron binding capacity | 323 | $5,380 | $9 |
| Telephone medical discussion with physician, 21-30 minutes | 48 | $4,504 | $78 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $4,482 | $140 |
| Cyanocobalamin (vitamin b-12) level | 235 | $3,988 | $15 |
| Iron level | 323 | $3,982 | $6 |
| Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | 48 | $3,896 | $50 |
| Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | 13 | $3,434 | $0 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 30 | $3,378 | $61 |
| Ct scan of chest without contrast | 23 | $3,087 | $106 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 59 | $2,875 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 47 | $2,873 | $17 |
| Administration of chemotherapy into vein, each additional hour | 37 | $2,741 | $24 |
| Folic acid level, serum | 167 | $2,596 | $14 |
| New patient visit (45+ min) | 19 | $2,389 | $126 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 28 | $2,331 | $27 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 16 | $1,876 | $20 |
| Psa (prostate specific antigen) measurement, total | 34 | $1,568 | $18 |
| Injection of additional new drug or substance into vein | 47 | $1,529 | $13 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 21 | $1,435 | $51 |
| Gammaglobulin (immune system protein) measurement | 88 | $1,431 | $9 |
| Telephone medical discussion with physician, 11-20 minutes | 26 | $1,332 | $49 |
| Administration of additional new drug or substance into vein using push technique | 11 | $1,319 | $47 |
| Declotting of central venous tube | 22 | $1,282 | $27 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 77 | $1,093 | $0 |
| Haptoglobin (serum protein) level | 79 | $1,023 | $12 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $968 | None |
| Flow cytometry technique for dna or cell analysis, first marker | 16 | $963 | $60 |
| Lactate dehydrogenase (enzyme) level | 102 | $841 | $6 |
| Injection, palonosetron hcl, 25 mcg | 40 | $821 | None |
| Injection, paclitaxel, 1 mg | 12 | $739 | None |
| Injection, carboplatin, 50 mg | 19 | $658 | None |
| Injection, fluorouracil, 500 mg | 11 | $652 | None |
| Blood test, thyroid stimulating hormone (tsh) | 30 | $510 | $16 |
| Red blood count, automated test | 101 | $414 | $4 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 106 | $365 | None |
| Urinalysis, manual test | 32 | $358 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 79 | $292 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $275 | $20 |
| Injection, testosterone cypionate, 1 mg | 17 | $274 | None |
| Blood test, clotting time | 22 | $260 | $4 |
| Unclassified drugs | 81 | $214 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 79 | $207 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 16 | $124 | None |
| Injection, magnesium sulfate, per 500 mg | 15 | $97 | None |
2022: 94 services
| Injection, atezolizumab, 10 mg | 13 | $482,458 | None |
| Injection, pembrolizumab, 1 mg | 11 | $481,294 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 38 | $366,416 | None |
| Injection, nivolumab, 1 mg | 20 | $277,940 | None |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 20 | $268,891 | $35 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 96 | $246,943 | None |
| Injection, denosumab, 1 mg | 80 | $246,906 | None |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 101 | $218,532 | $1,132 |
| Injection, paclitaxel protein-bound particles, 1 mg | 12 | $146,472 | None |
| Return visit (30+ min) | 534 | $127,663 | $98 |
| Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 33 | $121,191 | $177 |
| Injection, ferric carboxymaltose, 1 mg | 103 | $112,389 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 11 | $79,180 | None |
| Long return visit (40+ min) | 159 | $64,868 | $144 |
| Unclassified biologics | 11 | $58,141 | None |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 109 | $48,238 | $280 |
| Administration of chemotherapy into vein, 1 hour or less | 130 | $47,881 | $114 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 12 | $30,738 | None |
| Injection, granisetron, extended-release, 0.1 mg | 22 | $26,473 | None |
| New patient visit (60+ min) | 136 | $23,513 | $173 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 156 | $19,231 | $55 |
| Blood test, comprehensive group of blood chemicals | 564 | $18,859 | $10 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 565 | $17,456 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 137 | $14,696 | $25 |
| Injection of drug or substance under skin or into muscle | 336 | $13,064 | $11 |
| Administration of additional new drug or substance into vein, 1 hour or less | 56 | $12,945 | $57 |
| Ct scan of abdomen and pelvis with contrast | 40 | $12,928 | $235 |
| Short return visit (20+ min) | 105 | $12,580 | $71 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $12,164 | None |
| Flow cytometry technique for dna or cell analysis, each additional marker | 31 | $11,457 | $17 |
| Electrophoresis, laboratory testing technique | 112 | $9,515 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $9,086 | $159 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $8,246 | $82 |
| Ferritin (blood protein) level | 312 | $7,678 | $13 |
| Carcinoembryonic antigen (cea) protein level | 133 | $7,021 | $19 |
| Ct scan of chest with contrast | 51 | $6,665 | $83 |
| Telephone medical discussion with physician, 21-30 minutes | 58 | $5,429 | $86 |
| Injection, alteplase recombinant, 1 mg | 20 | $5,105 | None |
| Iron binding capacity | 312 | $5,063 | $9 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 13 | $5,059 | $145 |
| Insertion of needle into vein for collection of blood sample | 508 | $4,625 | $3 |
| Cyanocobalamin (vitamin b-12) level | 250 | $4,603 | $15 |
| Ct scan of chest without contrast | 26 | $3,908 | $91 |
| Iron level | 312 | $3,749 | $6 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 24 | $3,546 | $63 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 55 | $3,482 | $17 |
| Folic acid level, serum | 185 | $3,026 | $14 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 62 | $3,021 | $21 |
| Administration of chemotherapy into vein, each additional hour | 39 | $2,997 | $25 |
| Injection, aprepitant, 1 mg | 12 | $2,914 | None |
| Ct scan of abdomen and pelvis without contrast | 14 | $2,641 | $132 |
| Injection of additional new drug or substance into vein | 54 | $2,589 | $13 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 20 | $2,212 | $25 |
| Administration of additional new drug or substance into vein using push technique | 15 | $2,091 | $48 |
| Telephone medical discussion with physician, 11-20 minutes | 28 | $1,924 | $64 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 15 | $1,894 | $21 |
| Psa (prostate specific antigen) measurement, total | 37 | $1,821 | $18 |
| Injection, fosaprepitant, 1 mg | 33 | $1,783 | None |
| Flow cytometry technique for dna or cell analysis, first marker | 31 | $1,563 | $50 |
| Blood test, thyroid stimulating hormone (tsh) | 74 | $1,445 | $17 |
| Injection, leucovorin calcium, per 50 mg | 12 | $1,411 | None |
| Gammaglobulin (immune system protein) measurement | 77 | $1,218 | $9 |
| Injection, palonosetron hcl, 25 mcg | 46 | $1,206 | None |
| Drawing of blood for a medical problem | 11 | $1,128 | $87 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 14 | $1,123 | None |
| Declotting of central venous tube | 16 | $1,004 | $28 |
| Injection, carboplatin, 50 mg | 27 | $987 | None |
| Lactate dehydrogenase (enzyme) level | 113 | $918 | $6 |
| Injection, paclitaxel, 1 mg | 12 | $891 | None |
| Haptoglobin (serum protein) level | 64 | $845 | $12 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 73 | $842 | $0 |
| Influenza vaccine split virus, preservative free | 12 | $815 | $68 |
| Vitamin d-3 level | 20 | $675 | $29 |
| Injection, fluorouracil, 500 mg | 14 | $588 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 116 | $537 | None |
| Administration of influenza virus vaccine | 13 | $400 | $31 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 14 | $394 | $16 |
| Injection, oxaliplatin, 0.5 mg | 11 | $336 | None |
| Blood test, clotting time | 35 | $327 | $4 |
| Red blood count, automated test | 80 | $323 | $4 |
| Injection, testosterone cypionate, 1 mg | 11 | $322 | None |
| Application of on-body injector for under skin injection | 12 | $305 | $15 |
| Urinalysis, manual test | 35 | $298 | $3 |
| Injection, magnesium sulfate, per 500 mg | 12 | $280 | None |
| Beta-2 microglobulin (protein) level | 14 | $271 | $16 |
| Injection, dexamethasone sodium phosphate, 1 mg | 83 | $237 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $233 | $19 |
| Injection, diphenhydramine hcl, up to 50 mg | 86 | $222 | None |
| Thyroxine (thyroid chemical), free | 13 | $133 | $9 |
| Unclassified drugs | 80 | $132 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 18 | $131 | None |
| Coagulation assessment blood test, plasma or whole blood | 19 | $125 | $6 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 15 | $81 | $4 |
| Injection, potassium chloride, per 2 meq | 11 | $41 | None |
2021: 91 services
| Injection, atezolizumab, 10 mg | 17 | $655,478 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 22 | $330,112 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 94 | $275,112 | None |
| Injection, denosumab, 1 mg | 61 | $228,133 | None |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 102 | $209,075 | $1,349 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 14 | $200,934 | $44 |
| Return visit (30+ min) | 538 | $169,886 | $102 |
| Injection, paclitaxel protein-bound particles, 1 mg | 17 | $149,234 | None |
| Injection, ferric carboxymaltose, 1 mg | 125 | $141,937 | None |
| Injection, pegfilgrastim, 6 mg | 18 | $94,180 | None |
| Long return visit (40+ min) | 191 | $82,515 | $146 |
| Administration of chemotherapy into vein, 1 hour or less | 108 | $67,363 | $122 |
| Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 15 | $61,853 | $258 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 112 | $45,803 | $268 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 171 | $24,705 | $61 |
| Nuclear medicine study whole body with ct scan | 11 | $23,068 | $1,357 |
| Blood test, comprehensive group of blood chemicals | 538 | $21,647 | $11 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 546 | $19,940 | $8 |
| New patient visit (60+ min) | 110 | $18,603 | $169 |
| Flow cytometry technique for dna or cell analysis, each additional marker | 36 | $18,480 | $19 |
| Injection, granisetron, extended-release, 0.1 mg | 17 | $18,280 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 102 | $16,205 | $26 |
| Ct scan of abdomen and pelvis with contrast | 40 | $14,797 | $274 |
| Injection of drug or substance under skin or into muscle | 283 | $12,184 | $11 |
| Administration of additional new drug or substance into vein, 1 hour or less | 44 | $11,374 | $60 |
| Short return visit (20+ min) | 86 | $8,412 | $73 |
| Electrophoresis, laboratory testing technique | 94 | $8,180 | $62 |
| Ferritin (blood protein) level | 298 | $8,126 | $14 |
| Carcinoembryonic antigen (cea) protein level | 137 | $6,996 | $19 |
| Ct scan of chest with contrast | 44 | $6,956 | $118 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $5,799 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,538 | $163 |
| Iron binding capacity | 293 | $5,226 | $9 |
| Telephone medical discussion with physician, 21-30 minutes | 42 | $5,188 | $106 |
| Insertion of needle into vein for collection of blood sample | 594 | $5,089 | $3 |
| Cyanocobalamin (vitamin b-12) level | 239 | $4,464 | $15 |
| Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 14 | $4,019 | $0 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 64 | $3,975 | $21 |
| Iron level | 294 | $3,877 | $6 |
| Ct scan of chest without contrast | 29 | $3,860 | $107 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $3,733 | $27 |
| Injection, alteplase recombinant, 1 mg | 16 | $3,363 | None |
| Telephone medical discussion with physician, 11-20 minutes | 37 | $3,323 | $74 |
| Administration of chemotherapy into vein, each additional hour | 34 | $3,213 | $26 |
| Injection, palonosetron hcl, 25 mcg | 32 | $3,170 | None |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 13 | $3,080 | $147 |
| Ct scan of abdomen and pelvis without contrast | 16 | $2,852 | $168 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 36 | $2,838 | $18 |
| Injection of additional new drug or substance into vein | 43 | $2,751 | $14 |
| Folic acid level, serum | 168 | $2,749 | $15 |
| Infusion into a vein for hydration, each additional hour | 34 | $2,729 | $12 |
| Injection, fosaprepitant, 1 mg | 24 | $2,398 | None |
| Flow cytometry technique for dna or cell analysis, first marker | 36 | $2,368 | $58 |
| Blood test, thyroid stimulating hormone (tsh) | 105 | $2,167 | $17 |
| Administration of additional new drug or substance into vein using push technique | 12 | $1,879 | $52 |
| Psa (prostate specific antigen) measurement, total | 39 | $1,802 | $17 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 18 | $1,644 | $21 |
| Gammaglobulin (immune system protein) measurement | 86 | $1,480 | $9 |
| Drawing of blood for a medical problem | 11 | $1,192 | $85 |
| Infusion into a vein for hydration, 31-60 minutes | 18 | $1,189 | $30 |
| Vitamin d-3 level | 33 | $1,125 | $30 |
| Influenza vaccine split virus, preservative free | 17 | $1,101 | $65 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | 14 | $1,061 | $21 |
| Lactate dehydrogenase (enzyme) level | 112 | $1,022 | $6 |
| Injection, paclitaxel, 1 mg | 14 | $1,006 | None |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 72 | $901 | $0 |
| Haptoglobin (serum protein) level | 61 | $805 | $13 |
| Injection, leucovorin calcium, per 50 mg | 11 | $702 | None |
| Injection, carboplatin, 50 mg | 18 | $683 | None |
| Application of on-body injector for under skin injection | 16 | $643 | $16 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 93 | $570 | None |
| Injection, testosterone cypionate, 1 mg | 14 | $435 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 66 | $406 | None |
| Urinalysis, manual test | 24 | $358 | $3 |
| Administration of influenza virus vaccine | 20 | $356 | $18 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 11 | $329 | None |
| Blood test, clotting time | 38 | $292 | $4 |
| Thyroxine (thyroid chemical), total | 35 | $282 | $7 |
| Injection, fluorouracil, 500 mg | 13 | $271 | None |
| Red blood count, automated test | 60 | $239 | $4 |
| Uric acid level, blood | 14 | $212 | $5 |
| Unclassified drugs | 59 | $169 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 55 | $167 | None |
| Magnesium level | 15 | $161 | $7 |
| Coagulation assessment blood test, plasma or whole blood | 22 | $132 | $6 |
| Infusion, normal saline solution , 1000 cc | 24 | $123 | None |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 21 | $90 | $4 |
| 5% dextrose/normal saline (500 ml = 1 unit) | 11 | $74 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 35 | $44 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 13 | $44 | None |
| Injection, heparin sodium, per 1000 units | 38 | $16 | None |
2020: 85 services
| Injection, atezolizumab, 10 mg | 19 | $563,974 | None |
| Injection, pembrolizumab, 1 mg | 12 | $506,260 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 87 | $311,802 | None |
| Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 15 | $295,268 | $50 |
| Injection, pegfilgrastim, 6 mg | 38 | $251,537 | None |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 123 | $213,242 | $1,308 |
| Injection, denosumab, 1 mg | 60 | $212,308 | None |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 13 | $195,260 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 15 | $136,681 | None |
| Return visit (30+ min) | 477 | $125,028 | $85 |
| Injection, ferric carboxymaltose, 1 mg | 94 | $107,669 | None |
| Administration of chemotherapy into vein, 1 hour or less | 108 | $60,078 | $116 |
| Long return visit (40+ min) | 167 | $47,936 | $118 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 135 | $35,324 | $196 |
| Unclassified drugs | 38 | $22,623 | None |
| Blood test, comprehensive group of blood chemicals | 517 | $21,573 | $10 |
| New patient visit (60+ min) | 134 | $21,499 | $160 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 530 | $19,753 | $8 |
| Nuclear medicine study whole body with ct scan | 12 | $19,576 | $1,305 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 132 | $19,203 | $59 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 96 | $15,752 | $25 |
| Ct scan of abdomen and pelvis with contrast | 36 | $13,038 | $277 |
| Administration of additional new drug or substance into vein, 1 hour or less | 50 | $12,376 | $58 |
| Flow cytometry technique for dna or cell analysis, each additional marker | 24 | $11,453 | $19 |
| Injection of drug or substance under skin or into muscle | 265 | $11,131 | $11 |
| Injection, fosaprepitant, 1 mg | 20 | $9,790 | None |
| Electrophoresis, laboratory testing technique | 105 | $9,641 | $61 |
| Ferritin (blood protein) level | 297 | $8,597 | $13 |
| Ct scan of chest with contrast | 50 | $7,592 | $127 |
| Carcinoembryonic antigen (cea) protein level | 137 | $7,422 | $19 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 11 | $7,376 | None |
| Injection, palonosetron hcl, 25 mcg | 45 | $7,094 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $7,020 | $86 |
| Insertion of needle into vein for collection of blood sample | 690 | $6,826 | $3 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $6,809 | $166 |
| Administration of chemotherapy into vein, each additional hour | 47 | $6,070 | $26 |
| Short return visit (20+ min) | 74 | $5,825 | $59 |
| Iron binding capacity | 295 | $5,600 | $9 |
| Cyanocobalamin (vitamin b-12) level | 246 | $4,889 | $15 |
| Iron level | 295 | $4,170 | $6 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 63 | $4,116 | $21 |
| Injection of additional new drug or substance into vein | 59 | $3,380 | $14 |
| Infusion into a vein for hydration, each additional hour | 27 | $3,366 | $11 |
| Folic acid level, serum | 182 | $3,084 | $15 |
| Ct scan of chest without contrast | 23 | $2,942 | $109 |
| Ct scan of abdomen and pelvis without contrast | 15 | $2,725 | $160 |
| Injection, alteplase recombinant, 1 mg | 11 | $2,624 | None |
| Telephone medical discussion with physician, 11-20 minutes | 36 | $2,510 | $63 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $2,425 | $24 |
| Blood test, thyroid stimulating hormone (tsh) | 107 | $2,289 | $17 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 26 | $1,985 | $18 |
| Psa (prostate specific antigen) measurement, total | 38 | $1,844 | $17 |
| Injection, carboplatin, 50 mg | 28 | $1,758 | None |
| Lactate dehydrogenase (enzyme) level | 168 | $1,684 | $6 |
| Injection, paclitaxel, 1 mg | 22 | $1,610 | None |
| Flow cytometry technique for dna or cell analysis, first marker | 25 | $1,569 | $58 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 16 | $1,528 | $21 |
| Gammaglobulin (immune system protein) measurement | 65 | $1,302 | $9 |
| Application of on-body injector for under skin injection | 31 | $1,162 | $17 |
| Infusion into a vein for hydration, 31-60 minutes | 13 | $1,079 | $28 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 49 | $1,011 | None |
| Influenza vaccine split virus, preservative free | 16 | $976 | $61 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | 14 | $929 | $21 |
| Haptoglobin (serum protein) level | 62 | $913 | $13 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 74 | $811 | $0 |
| Irrigation of implanted venous access drug delivery device | 13 | $806 | $22 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $804 | $50 |
| Vitamin d-3 level | 23 | $795 | $29 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 108 | $532 | None |
| Injection of drug or substance into vein | 13 | $505 | $34 |
| Urinalysis, manual test | 42 | $488 | $3 |
| Uric acid level, blood | 19 | $414 | $5 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $407 | $18 |
| Thyroxine (thyroid chemical), total | 41 | $396 | $7 |
| Blood test, clotting time | 52 | $345 | $4 |
| Injection, dexamethasone sodium phosphate, 1 mg | 64 | $320 | None |
| Administration of influenza virus vaccine | 18 | $318 | $18 |
| Injection, testosterone cypionate, 1 mg | 11 | $271 | None |
| Red blood count, automated test | 59 | $245 | $4 |
| Beta-2 microglobulin (protein) level | 12 | $192 | $16 |
| Injection, diphenhydramine hcl, up to 50 mg | 59 | $158 | None |
| Coagulation assessment blood test, plasma or whole blood | 19 | $125 | $6 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 20 | $97 | $4 |
| Infusion, normal saline solution , 1000 cc | 11 | $85 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 24 | $37 | None |
2019: 72 services
| Injection, pegfilgrastim, 6 mg | 23 | $301,182 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 66 | $282,107 | None |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 84 | $186,718 | $1,253 |
| Injection, denosumab, 1 mg | 38 | $168,906 | None |
| Return visit (30+ min) | 419 | $122,834 | $85 |
| Injection, ferric carboxymaltose, 1 mg | 77 | $95,072 | None |
| Administration of chemotherapy into vein, 1 hour or less | 47 | $45,668 | $119 |
| Long return visit (40+ min) | 121 | $32,220 | $115 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 89 | $30,926 | $195 |
| Blood test, comprehensive group of blood chemicals | 469 | $22,652 | $12 |
| New patient visit (60+ min) | 143 | $22,499 | $157 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 481 | $20,506 | $8 |
| Ct scan of abdomen and pelvis with contrast | 44 | $15,753 | $267 |
| Injection, aprepitant, 1 mg | 17 | $15,736 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 101 | $14,703 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $12,681 | $84 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 16 | $12,358 | $1 |
| Injection of drug or substance under skin or into muscle | 152 | $11,757 | $13 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 42 | $10,794 | $26 |
| Electrophoresis, laboratory testing technique | 119 | $10,246 | $60 |
| Administration of additional new drug or substance into vein, 1 hour or less | 23 | $9,597 | $57 |
| Ferritin (blood protein) level | 296 | $9,565 | $15 |
| Injection, palonosetron hcl, 25 mcg | 21 | $8,647 | None |
| Ct scan of chest with contrast | 51 | $7,755 | $125 |
| Carcinoembryonic antigen (cea) protein level | 128 | $7,372 | $21 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $7,040 | $160 |
| Insertion of needle into vein for collection of blood sample | 486 | $6,468 | $3 |
| Iron binding capacity | 296 | $6,321 | $10 |
| Cyanocobalamin (vitamin b-12) level | 277 | $6,320 | $16 |
| Iron level | 296 | $4,688 | $7 |
| Folic acid level, serum | 235 | $4,661 | $16 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 67 | $4,625 | $23 |
| Administration of chemotherapy into vein, each additional hour | 32 | $4,218 | $26 |
| Short return visit (20+ min) | 48 | $3,616 | $60 |
| Ct scan of chest without contrast | 26 | $3,248 | $102 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 53 | $3,133 | None |
| Ct scan of abdomen and pelvis without contrast | 15 | $3,125 | $164 |
| Infusion into a vein for hydration, each additional hour | 35 | $2,896 | $11 |
| Unclassified drugs | 16 | $2,873 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $2,583 | $25 |
| Psa (prostate specific antigen) measurement, total | 44 | $2,369 | $20 |
| Lactate dehydrogenase (enzyme) level | 169 | $2,211 | $7 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 18 | $2,199 | $23 |
| Blood test, thyroid stimulating hormone (tsh) | 71 | $1,757 | $18 |
| Injection of additional new drug or substance into vein | 28 | $1,720 | $14 |
| Injection, carboplatin, 50 mg | 14 | $1,476 | None |
| Gammaglobulin (immune system protein) measurement | 62 | $1,297 | $10 |
| Application of on-body injector for under skin injection | 22 | $1,252 | $17 |
| Influenza vaccine split virus, preservative free | 21 | $1,153 | $55 |
| Haptoglobin (serum protein) level | 79 | $1,136 | $14 |
| Infusion into a vein for hydration, 31-60 minutes | 15 | $1,120 | $32 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 15 | $1,033 | $18 |
| Vitamin d-3 level | 30 | $1,003 | $31 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 77 | $935 | $0 |
| Beta-2 microglobulin (protein) level | 21 | $616 | $18 |
| Administration of influenza virus vaccine | 29 | $503 | $17 |
| Uric acid level, blood | 13 | $487 | $5 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 58 | $456 | None |
| Thyroxine (thyroid chemical), total | 41 | $390 | $7 |
| Magnesium level | 13 | $379 | $7 |
| Blood test, clotting time | 39 | $360 | $4 |
| Red blood count, automated test | 74 | $331 | $4 |
| Urinalysis, manual test | 37 | $293 | $3 |
| Immunologic analysis technique on serum (immunofixation) | 11 | $268 | $24 |
| Injection, dexamethasone sodium phosphate, 1 mg | 33 | $216 | None |
| Coagulation assessment blood test, plasma or whole blood | 26 | $177 | $7 |
| Blood test, basic group of blood chemicals (calcium, total) | 14 | $157 | $9 |
| Infusion, normal saline solution , 1000 cc | 18 | $121 | None |
| Microscopic examination for white blood cells with manual cell count | 24 | $94 | $4 |
| Red blood cell sedimentation rate, to detect inflammation, automated | 27 | $85 | $3 |
| Injection, diphenhydramine hcl, up to 50 mg | 24 | $74 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 21 | $44 | None |
2018: 64 services
| Injection, pegfilgrastim, 6 mg | 22 | $216,932 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 46 | $161,683 | None |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 65 | $126,573 | $1,172 |
| Injection, denosumab, 1 mg | 24 | $124,084 | None |
| Return visit (30+ min) | 341 | $99,634 | $84 |
| Injection, ferric carboxymaltose, 1 mg | 44 | $51,430 | None |
| Administration of chemotherapy into vein, 1 hour or less | 37 | $25,379 | $119 |
| Long return visit (40+ min) | 107 | $22,906 | $115 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 67 | $21,567 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 80 | $18,810 | $84 |
| Injection, granisetron, extended-release, 0.1 mg | 12 | $18,177 | None |
| Blood test, comprehensive group of blood chemicals | 377 | $17,230 | $13 |
| New patient visit (60+ min) | 100 | $15,869 | $159 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 394 | $15,482 | $9 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 63 | $11,146 | $164 |
| Injection of drug or substance under skin or into muscle | 118 | $10,530 | $16 |
| Unclassified drugs | 18 | $9,780 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 60 | $9,608 | $60 |
| Ct scan of abdomen and pelvis with contrast | 30 | $8,925 | $223 |
| Electrophoresis, laboratory testing technique | 79 | $7,835 | $60 |
| Injection, palonosetron hcl, 25 mcg | 12 | $7,344 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 39 | $7,025 | $26 |
| Carcinoembryonic antigen (cea) protein level | 103 | $6,056 | $23 |
| Administration of additional new drug or substance into vein, 1 hour or less | 23 | $5,679 | $57 |
| Ferritin (blood protein) level | 203 | $5,031 | $16 |
| Ct scan of chest with contrast | 31 | $4,934 | $105 |
| Insertion of needle into vein for collection of blood sample | 409 | $4,908 | $3 |
| Cyanocobalamin (vitamin b-12) level | 208 | $4,778 | $18 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 60 | $4,232 | $25 |
| Folic acid level, serum | 176 | $3,720 | $18 |
| Iron binding capacity | 203 | $3,246 | $11 |
| Administration of chemotherapy into vein, each additional hour | 18 | $2,743 | $26 |
| Short return visit (20+ min) | 35 | $2,619 | $58 |
| Iron level | 204 | $2,420 | $8 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $1,979 | $25 |
| Psa (prostate specific antigen) measurement, total | 34 | $1,825 | $22 |
| Injection of additional new drug or substance into vein | 23 | $1,486 | $15 |
| Infusion into a vein for hydration, each additional hour | 16 | $1,477 | $12 |
| Ct scan of chest without contrast | 13 | $1,408 | $94 |
| Lactate dehydrogenase (enzyme) level | 128 | $1,394 | $7 |
| Blood test, thyroid stimulating hormone (tsh) | 47 | $1,303 | $20 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 16 | $1,108 | $25 |
| Gammaglobulin (immune system protein) measurement | 44 | $1,080 | $11 |
| Vitamin d-3 level | 28 | $1,043 | $35 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 19 | $1,029 | $18 |
| Haptoglobin (serum protein) level | 55 | $837 | $15 |
| Irrigation of implanted venous access drug delivery device | 11 | $755 | $24 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 50 | $686 | $0 |
| Application of on-body injector for under skin injection | 14 | $636 | $17 |
| Beta-2 microglobulin (protein) level | 20 | $607 | $20 |
| Thyroxine (thyroid chemical), total | 35 | $367 | $8 |
| Magnesium level | 16 | $348 | $8 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 45 | $341 | None |
| Administration of influenza virus vaccine | 13 | $279 | $21 |
| Blood test, clotting time | 22 | $252 | $5 |
| Microscopic examination for white blood cells with manual cell count | 53 | $229 | $4 |
| Urinalysis, manual test | 22 | $181 | $3 |
| Blood test, basic group of blood chemicals (calcium, total) | 13 | $164 | $10 |
| Injection, dexamethasone sodium phosphate, 1 mg | 31 | $153 | None |
| Red blood count, automated test | 31 | $150 | $5 |
| Coagulation assessment blood test, plasma or whole blood | 16 | $124 | $7 |
| Red blood cell sedimentation rate, to detect inflammation, automated | 23 | $88 | $3 |
| Infusion, normal saline solution , 1000 cc | 13 | $56 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 22 | $43 | None |
2017: 62 services
| Injection, pegfilgrastim, 6 mg | 23 | $268,988 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 36 | $123,529 | None |
| Return visit (30+ min) | 334 | $103,752 | $84 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 62 | $101,556 | $1,116 |
| Injection, denosumab, 1 mg | 22 | $82,827 | None |
| Injection, ferric carboxymaltose, 1 mg | 42 | $57,002 | None |
| Administration of chemotherapy into vein, 1 hour or less | 57 | $35,297 | $115 |
| Injection, palonosetron hcl, 25 mcg | 29 | $24,527 | None |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 67 | $20,150 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 77 | $18,850 | $84 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 401 | $17,491 | $10 |
| Long return visit (40+ min) | 78 | $16,349 | $117 |
| Blood test, comprehensive group of blood chemicals | 335 | $16,135 | $13 |
| New patient visit (60+ min) | 95 | $15,432 | $162 |
| Injection, fosaprepitant, 1 mg | 16 | $11,556 | None |
| Injection of drug or substance under skin or into muscle | 99 | $10,171 | $21 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 60 | $8,986 | $58 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 56 | $8,659 | $26 |
| Carcinoembryonic antigen (cea) protein level | 101 | $7,622 | $25 |
| Administration of additional new drug or substance into vein, 1 hour or less | 29 | $6,766 | $55 |
| Short return visit (20+ min) | 80 | $5,614 | $53 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 71 | $5,428 | $28 |
| Ferritin (blood protein) level | 185 | $5,268 | $18 |
| Electrophoresis, laboratory testing technique | 84 | $5,080 | $46 |
| Insertion of needle into vein for collection of blood sample | 405 | $4,849 | $3 |
| Cyanocobalamin (vitamin b-12) level | 177 | $4,827 | $20 |
| Ct scan of abdomen and pelvis with contrast | 27 | $4,817 | $161 |
| Administration of chemotherapy into vein, each additional hour | 35 | $4,082 | $24 |
| Folic acid level, serum | 159 | $4,075 | $20 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,940 | $164 |
| Injection of additional new drug or substance into vein | 38 | $3,647 | $19 |
| Ct scan of chest with contrast | 35 | $3,530 | $86 |
| Administration of additional new drug or substance into vein using push technique | 11 | $3,051 | $53 |
| Iron binding capacity | 175 | $2,406 | $9 |
| Iron level | 176 | $2,231 | $9 |
| New patient visit (45+ min) | 19 | $2,086 | $110 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 22 | $1,850 | $15 |
| Psa (prostate specific antigen) measurement, total | 26 | $1,717 | $25 |
| Blood test, thyroid stimulating hormone (tsh) | 52 | $1,559 | $23 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | 12 | $1,175 | $28 |
| Injection of drug or substance into vein | 17 | $1,113 | $46 |
| Haptoglobin (serum protein) level | 58 | $1,065 | $17 |
| Lactate dehydrogenase (enzyme) level | 107 | $827 | $5 |
| Infusion into a vein for hydration, each additional hour | 14 | $819 | $12 |
| Vitamin d-3 level | 16 | $677 | $40 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 54 | $598 | $0 |
| Gammaglobulin (immune system protein) measurement | 29 | $590 | $9 |
| Blood test, basic group of blood chemicals (calcium, total) | 38 | $565 | $11 |
| Irrigation of implanted venous access drug delivery device | 12 | $527 | $20 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 43 | $478 | $9 |
| Blood test, clotting time | 22 | $354 | $5 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 31 | $316 | None |
| Red blood count, automated test | 49 | $274 | $5 |
| Thyroxine (thyroid chemical), total | 20 | $268 | $9 |
| Microscopic examination for white blood cells with manual cell count | 43 | $259 | $5 |
| Injection, dexamethasone sodium phosphate, 1 mg | 40 | $232 | None |
| Uric acid level, blood | 14 | $171 | $4 |
| Urinalysis, manual test | 13 | $117 | $3 |
| Red blood cell sedimentation rate, to detect inflammation, automated | 17 | $83 | $4 |
| Injection, atropine sulfate, 0.01 mg | 11 | $49 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 30 | $44 | None |
| Infusion, normal saline solution , 1000 cc | 12 | $25 | None |
2016: 62 services
| Injection, pegfilgrastim, 6 mg | 24 | $243,475 | None |
| Injection, denosumab, 1 mg | 14 | $96,615 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 29 | $93,640 | None |
| Return visit (30+ min) | 231 | $69,206 | $85 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 40 | $61,990 | $1,088 |
| Injection, ferric carboxymaltose, 1 mg | 50 | $44,484 | None |
| Administration of chemotherapy into vein, 1 hour or less | 51 | $25,527 | $111 |
| Injection, palonosetron hcl, 25 mcg | 30 | $17,765 | None |
| Short return visit (20+ min) | 159 | $14,509 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $12,254 | $83 |
| Long return visit (40+ min) | 58 | $12,163 | $116 |
| Blood test, comprehensive group of blood chemicals | 259 | $12,035 | $13 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 295 | $11,757 | $10 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 41 | $11,238 | $194 |
| Injection of drug or substance under skin or into muscle | 77 | $7,312 | $20 |
| Injection, fosaprepitant, 1 mg | 13 | $6,945 | None |
| New patient visit (60+ min) | 41 | $6,542 | $160 |
| Ct scan of abdomen and pelvis before and after contrast | 29 | $6,535 | $204 |
| Administration of additional new drug or substance into vein, 1 hour or less | 32 | $6,324 | $53 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 48 | $6,146 | $26 |
| Carcinoembryonic antigen (cea) protein level | 80 | $5,778 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 57 | $5,613 | $58 |
| New patient visit (45+ min) | 39 | $4,847 | $124 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 54 | $4,723 | $28 |
| Ct scan of chest with contrast | 34 | $4,360 | $95 |
| Injection of additional new drug or substance into vein | 45 | $3,397 | $19 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $3,146 | $63 |
| Cyanocobalamin (vitamin b-12) level | 122 | $3,120 | $20 |
| Insertion of needle into vein for collection of blood sample | 296 | $3,011 | $3 |
| Ferritin (blood protein) level | 116 | $2,948 | $18 |
| Folic acid level, serum | 108 | $2,630 | $20 |
| Electrophoresis, laboratory testing technique | 42 | $2,522 | $46 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,297 | $164 |
| Administration of chemotherapy into vein, each additional hour | 27 | $2,117 | $24 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $2,035 | $27 |
| Injection of drug or substance into vein | 24 | $1,519 | $46 |
| Iron binding capacity | 105 | $1,309 | $9 |
| Iron level | 105 | $1,210 | $9 |
| Psa (prostate specific antigen) measurement, total | 17 | $1,203 | $25 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 98 | $1,139 | $9 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 14 | $895 | $16 |
| Lactate dehydrogenase (enzyme) level | 91 | $821 | $4 |
| Blood test, basic group of blood chemicals (calcium, total) | 59 | $813 | $11 |
| Blood test, thyroid stimulating hormone (tsh) | 31 | $807 | $22 |
| Irrigation of implanted venous access drug delivery device | 19 | $717 | $21 |
| Infusion into a vein for hydration, each additional hour | 12 | $641 | $13 |
| Microscopic examination for white blood cells with manual cell count | 99 | $610 | $5 |
| Injection, carboplatin, 50 mg | 12 | $578 | None |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 43 | $532 | $0 |
| Haptoglobin (serum protein) level | 24 | $420 | $17 |
| Blood test, clotting time | 16 | $294 | $5 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 26 | $261 | None |
| Uric acid level, blood | 18 | $248 | $4 |
| Injection, dexamethasone sodium phosphate, 1 mg | 45 | $247 | None |
| Gammaglobulin (immune system protein) measurement | 13 | $236 | $9 |
| Thyroxine (thyroid chemical), total | 17 | $165 | $9 |
| Red blood count, automated test | 22 | $117 | $5 |
| Blood creatinine level | 23 | $88 | $4 |
| Urea nitrogen level to assess kidney function, quantitative | 23 | $81 | $3 |
| Urinalysis, manual test | 13 | $58 | $3 |
| Red blood cell sedimentation rate, to detect inflammation, automated | 11 | $47 | $4 |
| Injection, diphenhydramine hcl, up to 50 mg | 28 | $32 | None |
2015: 59 services
| Injection, pegfilgrastim, 6 mg | 18 | $153,115 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 31 | $101,961 | None |
| Return visit (30+ min) | 212 | $49,625 | $86 |
| Injection, ferric carboxymaltose, 1 mg | 27 | $26,878 | None |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 18 | $20,739 | $1,092 |
| Long return visit (40+ min) | 61 | $19,109 | $114 |
| Administration of chemotherapy into vein, 1 hour or less | 39 | $15,281 | $110 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $15,150 | $85 |
| Short return visit (20+ min) | 161 | $14,190 | $55 |
| Injection, palonosetron hcl, 25 mcg | 18 | $12,954 | None |
| Injection, fosaprepitant, 1 mg | 12 | $10,981 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 310 | $9,896 | $10 |
| Blood test, comprehensive group of blood chemicals | 221 | $8,196 | $13 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 48 | $6,617 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 53 | $6,470 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $6,405 | $164 |
| Injection of drug or substance under skin or into muscle | 86 | $6,085 | $21 |
| New patient visit (60+ min) | 24 | $4,058 | $169 |
| Carcinoembryonic antigen (cea) protein level | 63 | $4,021 | $25 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 18 | $3,742 | $197 |
| Ct scan of abdomen and pelvis before and after contrast | 12 | $3,080 | $220 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 42 | $2,914 | $28 |
| Administration of additional new drug or substance into vein, 1 hour or less | 16 | $2,910 | $53 |
| Insertion of needle into vein for collection of blood sample | 259 | $2,333 | $3 |
| New patient visit (45+ min) | 18 | $2,332 | $130 |
| Ferritin (blood protein) level | 95 | $2,291 | $18 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $2,272 | $63 |
| Administration of chemotherapy into vein, each additional hour | 18 | $2,127 | $24 |
| Electrophoresis, laboratory testing technique | 38 | $1,975 | $45 |
| Injection of additional new drug or substance into vein | 24 | $1,966 | $19 |
| Cyanocobalamin (vitamin b-12) level | 82 | $1,889 | $20 |
| Ct scan of chest with contrast | 13 | $1,527 | $95 |
| Folic acid level, serum | 71 | $1,414 | $19 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 82 | $1,235 | $9 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 19 | $1,165 | $16 |
| Blood test, basic group of blood chemicals (calcium, total) | 64 | $1,096 | $11 |
| Iron binding capacity | 88 | $991 | $9 |
| Iron level | 88 | $924 | $9 |
| Psa (prostate specific antigen) measurement, total | 13 | $859 | $25 |
| Microscopic examination for white blood cells with manual cell count | 81 | $634 | $5 |
| Blood test, thyroid stimulating hormone (tsh) | 25 | $605 | $22 |
| Infusion into a vein for hydration, each additional hour | 13 | $423 | $12 |
| Lactate dehydrogenase (enzyme) level | 57 | $407 | $4 |
| Haptoglobin (serum protein) level | 22 | $405 | $16 |
| Irrigation of implanted venous access drug delivery device | 11 | $317 | $20 |
| Blood test, clotting time | 21 | $288 | $5 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 21 | $272 | $0 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 33 | $252 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 33 | $223 | None |
| Uric acid level, blood | 27 | $193 | $3 |
| Gammaglobulin (immune system protein) measurement | 14 | $175 | $9 |
| Thyroxine (thyroid chemical), total | 16 | $165 | $9 |
| Red blood count, automated test | 23 | $123 | $5 |
| Blood creatinine level | 20 | $69 | $3 |
| Urea nitrogen level to assess kidney function, quantitative | 20 | $69 | $3 |
| Phosphate level | 20 | $63 | $3 |
| Glutamyltransferase (liver enzyme) level | 13 | $55 | $4 |
| Urinalysis, manual test | 14 | $55 | $3 |
| Injection, diphenhydramine hcl, up to 50 mg | 25 | $34 | None |
2014: 12 services
| Return visit (30+ min) | 31 | $3,074 | $88 |
| New patient visit (45+ min) | 12 | $1,612 | $134 |
| Blood test, comprehensive group of blood chemicals | 30 | $437 | $12 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 33 | $416 | $10 |
| Cyanocobalamin (vitamin b-12) level | 15 | $343 | $20 |
| Folic acid level, serum | 15 | $315 | $20 |
| Ferritin (blood protein) level | 13 | $273 | $18 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 27 | $242 | $9 |
| Microscopic examination for white blood cells with manual cell count | 27 | $124 | $5 |
| Iron binding capacity | 12 | $122 | $9 |
| Insertion of needle into vein for collection of blood sample | 30 | $115 | $3 |
| Iron level | 12 | $112 | $9 |
Medicaid work
$51,409 in 2024
Medicaid paid $51,409 for 11,228 billed services this clinician did in 2024, up to 132 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Denosumab injection | 64 | $11,760 |
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 94 | $7,060 |
| Return visit (30+ min) | 984 | $4,555 |
| Injection, ferric carboxymaltose, 1 mg | 39 | $4,054 |
| New patient visit (60+ min) | 190 | $3,108 |
| Long return visit (40+ min) | 474 | $2,728 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 342 | $1,945 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 71 | $1,890 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 572 | $1,463 |
| Short return visit (20+ min) | 287 | $1,458 |
| COMPREHENSIVE METABOLIC PANEL | 1,102 | $1,330 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 81 | $1,054 |
| 2024 | 11,228 | 44 | 132 | $51,409 |
| 2023 | 12,319 | 42 | 133 | $70,575 |
| 2022 | 10,649 | 40 | 132 | $31,352 |
| 2021 | 5,850 | 27 | 73 | $18,210 |
| 2020 | 6,285 | 26 | 110 | $37,281 |
| 2019 | 7,110 | 25 | 87 | $26,976 |
| 2018 | 6,982 | 26 | 97 | $20,804 |
See the largest Medicaid services in earlier years
2023
| Injection, eflapegrastim-xnst, 0.1 mg | 16 | $10,386 |
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 75 | $8,825 |
| Denosumab injection | 43 | $8,284 |
| Injection, ferric carboxymaltose, 1 mg | 184 | $8,021 |
| Darbepoetin alfa, non-esrd | 112 | $6,497 |
| Long return visit (40+ min) | 593 | $4,458 |
| Return visit (30+ min) | 1,154 | $4,101 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 443 | $2,983 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 99 | $2,919 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 582 | $2,030 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 1,182 | $1,609 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 394 | $1,545 |
2022
| Injection, ferric carboxymaltose, 1 mg | 200 | $11,263 |
| Return visit (30+ min) | 1,136 | $3,394 |
| Denosumab injection | 31 | $2,930 |
| Long return visit (40+ min) | 394 | $2,547 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 379 | $1,310 |
| New patient visit (60+ min) | 134 | $1,308 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 419 | $1,290 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 69 | $1,062 |
| COMPREHENSIVE METABOLIC PANEL | 1,302 | $1,058 |
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 31 | $957 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 310 | $942 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 1,507 | $833 |
2021
| Injection, ferric carboxymaltose, 1 mg | 84 | $4,461 |
| Return visit (30+ min) | 875 | $3,856 |
| Long return visit (40+ min) | 287 | $2,544 |
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 13 | $1,627 |
| COMPREHENSIVE METABOLIC PANEL | 674 | $868 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 219 | $846 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 756 | $748 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 27 | $648 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 323 | $581 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 585 | $497 |
| New patient visit (60+ min) | 36 | $476 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 144 | $338 |
2020
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 57 | $10,348 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 653 | $6,787 |
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 53 | $5,266 |
| Return visit (30+ min) | 1,018 | $4,436 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 34 | $3,233 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 963 | $1,350 |
| Long return visit (40+ min) | 223 | $1,349 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 460 | $1,130 |
| COMPREHENSIVE METABOLIC PANEL | 816 | $1,086 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 363 | $695 |
| New patient visit (60+ min) | 44 | $454 |
| Darbepoetin alfa, non-esrd | 30 | $214 |
2019
| Injection, ferric carboxymaltose, 1 mg | 44 | $8,025 |
| Return visit (30+ min) | 846 | $6,641 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 292 | $1,939 |
| Long return visit (40+ min) | 170 | $1,911 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 1,095 | $1,674 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 384 | $1,576 |
| COMPREHENSIVE METABOLIC PANEL | 970 | $1,519 |
| Darbepoetin alfa, non-esrd | 64 | $554 |
| Short return visit (20+ min) | 153 | $483 |
| New patient visit (60+ min) | 60 | $431 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 537 | $428 |
| CARCINOEMBRYONIC ANTIGEN | 350 | $349 |
2018
| Return visit (30+ min) | 1,070 | $5,531 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 471 | $3,992 |
| Injection, dexamethasone sodium phosphate, 1 mg | 329 | $2,067 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 351 | $2,025 |
| COMPREHENSIVE METABOLIC PANEL | 1,117 | $1,928 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 317 | $1,026 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 1,103 | $764 |
| Long return visit (40+ min) | 76 | $753 |
| New patient visit (60+ min) | 92 | $479 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 89 | $472 |
| CARCINOEMBRYONIC ANTIGEN | 219 | $329 |
| Palonosetron hcl | 43 | $213 |
Drugs they prescribed that Part D paid
$3,333,426
Pharmacies billed $3,333,426 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 10% of their Part D prescriptions (130 of 1,371) in 2024. A higher opioid share than 9 in 10 peers; the typical internal medicine clinician is at 1%.
1,091 generic and 280 brand-name prescriptions · $3,333,426 in drug cost · 61 antibiotic prescriptions to 38 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lenalidomide | 33 | $594,741 | $18,022 |
| Ibrance | 29 | $446,454 | $15,395 |
| Xtandi | 27 | $371,783 | $13,770 |
| Lynparza | 12 | $200,807 | $16,734 |
| Verzenio | 13 | $186,677 | $14,360 |
See all 30 drugs
| Lenalidomide | 33 | $594,741 | $18,022 |
| Ibrance | 29 | $446,454 | $15,395 |
| Xtandi | 27 | $371,783 | $13,770 |
| Lynparza | 12 | $200,807 | $16,734 |
| Verzenio | 13 | $186,677 | $14,360 |
| Abiraterone Acetate | 43 | $98,410 | $2,289 |
| Eliquis | 36 | $32,756 | $910 |
| Xarelto | 18 | $27,548 | $1,530 |
| Letrozole | 175 | $5,070 | $29 |
| Clinisol | 12 | $3,817 | $318 |
| Anastrozole | 108 | $3,186 | $30 |
| Ondansetron Odt | 57 | $2,403 | $42 |
| Hydrocodone-Acetaminophen | 60 | $1,355 | $23 |
| Gabapentin | 56 | $1,046 | $19 |
| Hydroxyurea | 26 | $950 | $37 |
| Prochlorperazine Maleate | 42 | $659 | $16 |
| Tamoxifen Citrate | 28 | $650 | $23 |
| Loperamide | 19 | $500 | $26 |
| Morphine Sulfate | 21 | $490 | $23 |
| Tramadol | 24 | $332 | $14 |
| Prednisone | 35 | $183 | $5 |
| Ondansetron | 16 | $171 | $11 |
| Acyclovir | 19 | $157 | $8 |
| Dexamethasone | 12 | $150 | $13 |
| Potassium Chloride | 16 | $103 | $6 |
| Famotidine | 14 | $85 | $6 |
| Lorazepam | 24 | $48 | $2 |
| Ciprofloxacin | 12 | $22 | $2 |
| Levofloxacin | 11 | $21 | $2 |
| Furosemide | 12 | $21 | $2 |
Year by year
| 2024 | 1,371 | 294 | 10% (130) | 20% | $3,333,426 |
| 2023 | 1,059 | 234 | 9% (95) | None | $2,484,532 |
| 2022 | 1,139 | 232 | 7% (78) | 21% | $2,405,156 |
| 2021 | 1,061 | 223 | 7% (69) | 25% | $2,302,220 |
| 2020 | 1,185 | 221 | 9% (103) | 30% | $2,435,438 |
| 2019 | 1,138 | 192 | 12% (132) | None | $2,067,980 |
| 2018 | 915 | 147 | 17% (155) | None | $1,050,600 |
| 2017 | 939 | 152 | 13% (119) | None | $830,116 |
| 2016 | 804 | 127 | 15% (124) | 31% | $893,149 |
| 2015 | 467 | 90 | 16% (75) | None | $426,176 |
| 2014 | 26 | 15 | None | None | $987 |
| 2013 | 19 | 12 | None | None | $11,628 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 22 drugs
| Abiraterone Acetate | 68 | $314,623 | $4,627 |
| Imbruvica | 18 | $224,825 | $12,490 |
| Lenalidomide | 11 | $194,492 | $17,681 |
| Lynparza | 11 | $185,790 | $16,890 |
| Xarelto | 23 | $29,147 | $1,267 |
| Eliquis | 23 | $27,254 | $1,185 |
| Letrozole | 115 | $4,010 | $35 |
| Anastrozole | 79 | $2,651 | $34 |
| Ondansetron Odt | 44 | $2,020 | $46 |
| Hydrocodone-Acetaminophen | 48 | $1,609 | $34 |
| Tamoxifen Citrate | 25 | $1,108 | $44 |
| Gabapentin | 34 | $854 | $25 |
| Hydroxyurea | 22 | $840 | $38 |
| Prednisone | 48 | $406 | $8 |
| Prochlorperazine Maleate | 21 | $391 | $19 |
| Mirtazapine | 14 | $301 | $22 |
| Pantoprazole | 13 | $203 | $16 |
| Famotidine | 12 | $136 | $11 |
| Ciprofloxacin | 14 | $83 | $6 |
| Alprazolam | 19 | $81 | $4 |
| Potassium Chloride | 13 | $71 | $5 |
| Lorazepam | 22 | $27 | $1 |
2022: 34 drugs
| Revlimid | 20 | $411,200 | $20,560 |
| Abiraterone Acetate | 60 | $212,330 | $3,539 |
| Ibrance | 14 | $209,814 | $14,987 |
| Imbruvica | 13 | $193,560 | $14,889 |
| Lynparza | 11 | $183,246 | $16,659 |
| Xtandi | 11 | $157,653 | $14,332 |
| Kisqali | 11 | $144,108 | $13,101 |
| Eliquis | 47 | $39,484 | $840 |
| Imatinib Mesylate | 19 | $27,871 | $1,467 |
| Deferasirox | 12 | $21,108 | $1,759 |
| Xarelto | 16 | $20,778 | $1,299 |
| Ondansetron Odt | 47 | $3,294 | $70 |
| Letrozole | 79 | $2,867 | $36 |
| Ondansetron | 30 | $1,687 | $56 |
| Hydrocodone-Acetaminophen | 49 | $1,553 | $32 |
| Anastrozole | 73 | $1,535 | $21 |
| Prochlorperazine Maleate | 49 | $1,420 | $29 |
| Warfarin | 17 | $598 | $35 |
| Loperamide | 15 | $481 | $32 |
| Hydroxyurea | 22 | $466 | $21 |
| Prednisone | 61 | $415 | $7 |
| Levothyroxine | 23 | $348 | $15 |
| Tamoxifen Citrate | 14 | $266 | $19 |
| Dexamethasone | 15 | $230 | $15 |
| Cyclobenzaprine | 12 | $171 | $14 |
| Levetiracetam | 13 | $162 | $12 |
| Famotidine | 11 | $158 | $14 |
| Gabapentin | 13 | $153 | $12 |
| Pantoprazole | 12 | $149 | $12 |
| Lorazepam | 33 | $141 | $4 |
| Alprazolam | 20 | $132 | $7 |
| Potassium Chloride | 11 | $105 | $10 |
| Azithromycin | 12 | $69 | $6 |
| Sulfamethoxazole-Trimethoprim | 11 | $42 | $4 |
2021: 35 drugs
| Ibrance | 40 | $541,202 | $13,530 |
| Revlimid | 17 | $383,837 | $22,579 |
| Venclexta | 17 | $204,229 | $12,013 |
| Kisqali | 14 | $194,007 | $13,858 |
| Imbruvica | 12 | $167,247 | $13,937 |
| Xtandi | 11 | $138,117 | $12,556 |
| Abiraterone Acetate | 25 | $119,011 | $4,760 |
| Eliquis | 57 | $46,745 | $820 |
| Xarelto | 21 | $20,446 | $974 |
| Imatinib Mesylate | 20 | $6,066 | $303 |
| Ondansetron Odt | 46 | $2,525 | $55 |
| Anastrozole | 61 | $2,268 | $37 |
| Letrozole | 46 | $2,154 | $47 |
| Prochlorperazine Maleate | 34 | $959 | $28 |
| Hydrocodone-Acetaminophen | 35 | $889 | $25 |
| Ondansetron | 23 | $839 | $36 |
| Warfarin | 20 | $615 | $31 |
| Megestrol Acetate | 12 | $498 | $42 |
| Hydroxyurea | 17 | $491 | $29 |
| Potassium Chloride | 22 | $409 | $19 |
| Prednisone | 43 | $346 | $8 |
| Alprazolam | 30 | $345 | $11 |
| Levothyroxine | 16 | $255 | $16 |
| Dexamethasone | 13 | $210 | $16 |
| Loperamide | 11 | $204 | $19 |
| Levofloxacin | 27 | $197 | $7 |
| Famotidine | 20 | $163 | $8 |
| Gabapentin | 14 | $123 | $9 |
| Allopurinol | 14 | $122 | $9 |
| Azithromycin | 16 | $106 | $7 |
| Lorazepam | 23 | $84 | $4 |
| Metoclopramide | 14 | $72 | $5 |
| Ciprofloxacin | 13 | $65 | $5 |
| Tramadol | 14 | $39 | $3 |
| Furosemide | 11 | $13 | $1 |
2020: 34 drugs
| Ibrance | 40 | $500,135 | $12,503 |
| Revlimid | 27 | $414,422 | $15,349 |
| Jakafi | 21 | $300,023 | $14,287 |
| Venclexta | 17 | $177,684 | $10,452 |
| Imbruvica | 13 | $168,701 | $12,977 |
| Xtandi | 12 | $137,376 | $11,448 |
| Eliquis | 77 | $46,517 | $604 |
| Xarelto | 29 | $18,416 | $635 |
| Imatinib Mesylate | 18 | $12,405 | $689 |
| Shingrix | 12 | $1,890 | $157 |
| Anastrozole | 70 | $1,765 | $25 |
| Ondansetron Odt | 34 | $1,695 | $50 |
| Letrozole | 47 | $1,636 | $35 |
| Hydrocodone-Acetaminophen | 56 | $1,337 | $24 |
| Ondansetron | 28 | $976 | $35 |
| Prochlorperazine Maleate | 36 | $918 | $25 |
| Megestrol Acetate | 17 | $652 | $38 |
| Levothyroxine | 30 | $557 | $19 |
| Warfarin | 14 | $480 | $34 |
| Morphine Sulfate | 13 | $400 | $31 |
| Potassium Chloride | 17 | $297 | $17 |
| Gabapentin | 37 | $277 | $7 |
| Omeprazole | 19 | $238 | $13 |
| Loperamide | 12 | $197 | $16 |
| Levofloxacin | 42 | $196 | $5 |
| Acyclovir | 12 | $176 | $15 |
| Prednisone | 25 | $175 | $7 |
| Alprazolam | 24 | $164 | $7 |
| Allopurinol | 14 | $130 | $9 |
| Zolpidem | 16 | $100 | $6 |
| Tramadol | 11 | $46 | $4 |
| Metoclopramide | 11 | $45 | $4 |
| Lorazepam | 16 | $45 | $3 |
| Furosemide | 11 | $32 | $3 |
2019: 33 drugs
| Ibrance | 39 | $456,932 | $11,716 |
| Jakafi | 22 | $296,698 | $13,486 |
| Revlimid | 14 | $288,449 | $20,603 |
| Zejula | 14 | $231,627 | $16,545 |
| Xtandi | 13 | $155,423 | $11,956 |
| Venclexta | 13 | $106,245 | $8,173 |
| Imatinib Mesylate | 12 | $91,839 | $7,653 |
| Eliquis | 81 | $38,887 | $480 |
| Xarelto | 31 | $17,498 | $564 |
| Anastrozole | 60 | $1,607 | $27 |
| Anagrelide | 11 | $1,511 | $137 |
| Letrozole | 45 | $1,422 | $32 |
| Hydrocodone-Acetaminophen | 91 | $1,329 | $15 |
| Megestrol Acetate | 12 | $1,045 | $87 |
| Ondansetron Odt | 20 | $910 | $46 |
| Ondansetron | 30 | $784 | $26 |
| Fluconazole | 11 | $622 | $57 |
| Hydroxyurea | 14 | $613 | $44 |
| Prochlorperazine Maleate | 24 | $550 | $23 |
| Morphine Sulfate Er | 12 | $452 | $38 |
| Levothyroxine | 31 | $386 | $12 |
| Potassium Chloride | 18 | $352 | $20 |
| Levofloxacin | 36 | $333 | $9 |
| Omeprazole | 31 | $221 | $7 |
| Alprazolam | 15 | $156 | $10 |
| Allopurinol | 13 | $143 | $11 |
| Prednisone | 27 | $132 | $5 |
| Warfarin | 22 | $130 | $6 |
| Mirtazapine | 12 | $116 | $10 |
| Ibuprofen | 14 | $93 | $7 |
| Azithromycin | 13 | $77 | $6 |
| Lorazepam | 12 | $64 | $5 |
| Sulfamethoxazole-Trimethoprim | 19 | $53 | $3 |
2018: 27 drugs
| Ibrance | 24 | $268,145 | $11,173 |
| Xtandi | 17 | $193,355 | $11,374 |
| Imatinib Mesylate | 16 | $124,546 | $7,784 |
| Oxycontin | 21 | $42,804 | $2,038 |
| Xarelto | 34 | $15,539 | $457 |
| Eliquis | 29 | $12,538 | $432 |
| Exemestane | 15 | $5,088 | $339 |
| Megestrol Acetate | 22 | $4,988 | $227 |
| Anagrelide | 11 | $1,671 | $152 |
| Letrozole | 75 | $1,652 | $22 |
| Hydrocodone-Acetaminophen | 70 | $1,072 | $15 |
| Potassium Chloride | 18 | $1,012 | $56 |
| Hydroxyurea | 30 | $834 | $28 |
| Anastrozole | 34 | $707 | $21 |
| Ondansetron Odt | 30 | $685 | $23 |
| Morphine Sulfate Er | 13 | $542 | $42 |
| Prochlorperazine Maleate | 25 | $440 | $18 |
| Levofloxacin | 27 | $349 | $13 |
| Ondansetron | 15 | $298 | $20 |
| Oxycodone | 12 | $265 | $22 |
| Omeprazole | 22 | $134 | $6 |
| Prednisone | 21 | $127 | $6 |
| Acetaminophen-Codeine | 14 | $120 | $9 |
| Warfarin | 19 | $117 | $6 |
| Ibu | 12 | $111 | $9 |
| Cyclobenzaprine | 15 | $84 | $6 |
| Zolpidem | 11 | $59 | $5 |
2017: 23 drugs
| Ibrance | 19 | $207,734 | $10,933 |
| Revlimid | 17 | $178,443 | $10,497 |
| Oxycontin | 15 | $39,336 | $2,622 |
| Xarelto | 57 | $23,736 | $416 |
| Eliquis | 38 | $14,205 | $374 |
| Exemestane | 13 | $3,539 | $272 |
| Letrozole | 81 | $1,795 | $22 |
| Ondansetron Odt | 43 | $1,658 | $39 |
| Hydroxyurea | 53 | $1,135 | $21 |
| Morphine Sulfate | 17 | $910 | $54 |
| Morphine Sulfate Er | 11 | $744 | $68 |
| Hydrocodone-Acetaminophen | 58 | $696 | $12 |
| Ondansetron | 24 | $671 | $28 |
| Prochlorperazine Maleate | 35 | $648 | $19 |
| Anastrozole | 27 | $402 | $15 |
| Warfarin | 26 | $311 | $12 |
| Loperamide | 12 | $195 | $16 |
| Potassium Chloride | 18 | $185 | $10 |
| Levofloxacin | 21 | $175 | $8 |
| Prednisone | 25 | $126 | $5 |
| Alprazolam | 17 | $118 | $7 |
| Lorazepam | 19 | $105 | $6 |
| Azithromycin | 13 | $82 | $6 |
2016: 26 drugs
| Ibrance | 13 | $132,328 | $10,179 |
| Tarceva | 18 | $97,915 | $5,440 |
| Exjade | 13 | $67,105 | $5,162 |
| Oxycontin | 13 | $34,039 | $2,618 |
| Xarelto | 68 | $25,432 | $374 |
| Creon | 11 | $8,173 | $743 |
| Clinisol | 15 | $5,796 | $386 |
| Exemestane | 22 | $3,080 | $140 |
| Ondansetron | 33 | $1,623 | $49 |
| Hydrocodone-Acetaminophen | 52 | $1,136 | $22 |
| Megestrol Acetate | 19 | $725 | $38 |
| Letrozole | 33 | $699 | $21 |
| Hydroxyurea | 31 | $690 | $22 |
| Morphine Sulfate Er | 14 | $686 | $49 |
| Loperamide | 18 | $650 | $36 |
| Fluconazole | 12 | $635 | $53 |
| Morphine Sulfate | 13 | $570 | $44 |
| Ondansetron Odt | 23 | $564 | $25 |
| Prochlorperazine Maleate | 32 | $360 | $11 |
| Anastrozole | 13 | $316 | $24 |
| Omeprazole | 19 | $220 | $12 |
| Oxycodone | 11 | $214 | $19 |
| Allopurinol | 13 | $206 | $16 |
| Gabapentin | 19 | $189 | $10 |
| Warfarin | 24 | $169 | $7 |
| Levofloxacin | 14 | $124 | $9 |
2015: 12 drugs
| Tarceva | 14 | $65,686 | $4,692 |
| Oxycontin | 11 | $33,841 | $3,076 |
| Exemestane | 19 | $3,972 | $209 |
| Hydrocodone-Acetaminophen | 30 | $695 | $23 |
| Warfarin | 42 | $657 | $16 |
| Morphine Sulfate Er | 15 | $628 | $42 |
| Potassium Chloride | 15 | $397 | $26 |
| Hydroxyurea | 11 | $285 | $26 |
| Levofloxacin | 20 | $198 | $10 |
| Ondansetron | 16 | $192 | $12 |
| Prednisone | 20 | $125 | $6 |
| Prochlorperazine Maleate | 16 | $86 | $5 |
Money from drug and device companies
$9,882 in 2025
| 2025 | 26 | 75 | $6,708 | $9,882 |
| 2024 | 23 | 106 | $5,430 | $7,587 |
| 2023 | 29 | 97 | $5,745 | $7,380 |
| 2022 | 25 | 132 | $22,808 | $24,958 |
| 2021 | 32 | 241 | $5,955 | $8,440 |
| 2020 | 14 | 60 | $2,500 | $3,186 |
| 2019 | 24 | 71 | $1,953 | $3,354 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Exelixis | Cabometyx | $5,211 | 20 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $3,519 | 8 payments
|
| Corcept Therapeutics | None | $291 | 3 payments
|
| SpringWorks Therapeutics | Ogsiveo | $116 | 4 payments
|
| Novartis Pharmaceuticals | Scemblix | $108 | 4 payments
|
| Abbvie | Epkinly | $96 | 4 payments
|
See all 68 published payments
| Corcept Therapeutics | Meals · 2025-12-13 | None | $50 |
| Corcept Therapeutics | Meals · 2025-12-13 | None | $80 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-12-13 | Nubeqa | $26 |
| Corcept Therapeutics | Travel · 2025-12-12 | None | $161 |
| Novocure | Meals · 2025-12-08 | Optune Lua (Novottf-200t) | $18 |
| Janssen Biotech | Meals · 2025-12-05 | Tecvayli | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-05 | Enhertu | $25 |
| Genmab U.S. | Meals · 2025-12-04 | Epkinly | $27 |
| PharmaEssentia USA | Meals · 2025-11-21 | Besremi | $19 |
| Sobi | Meals · 2025-11-18 | Vonjo | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-12 | Lynparza | $21 |
| SpringWorks Therapeutics | Meals · 2025-11-08 | Ogsiveo | $34 |
| Merck Sharp & Dohme | Meals · 2025-10-21 | Keytruda | $19 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-20 | None | $15 |
| Novartis Pharmaceuticals | Meals · 2025-09-19 | Scemblix | $26 |
| Exelixis | Honoraria · 2025-09-18 | Cabometyx | $1,975 |
| Exelixis | Meals · 2025-09-06 | Cabometyx | $91 |
| Exelixis | Meals · 2025-09-06 | Cabometyx | $59 |
| Exelixis | Meals · 2025-09-06 | Cabometyx | $29 |
| Exelixis | Travel · 2025-09-06 | Cabometyx | $293 |
| Novartis Pharmaceuticals | Meals · 2025-09-03 | Pluvicto | $24 |
| Telix Pharmaceuticals | Meals · 2025-08-25 | Illuccix | $17 |
| Daiichi Sankyo | Meals · 2025-08-23 | Injectafer | $21 |
| PharmaEssentia USA | Meals · 2025-08-13 | Besremi | $24 |
| Tempus AI | Meals · 2025-07-30 | Xt Cdx | $28 |
| Abbvie | Meals · 2025-07-18 | Imbruvica | $27 |
| Exelixis | Meals · 2025-07-11 | Cabometyx | $28 |
| Exelixis | Honoraria · 2025-07-03 | Cabometyx | $1,383 |
| Exelixis | Travel · 2025-06-21 | Cabometyx | $202 |
| Exelixis | Travel · 2025-06-21 | Cabometyx | $30 |
| Exelixis | Meals · 2025-06-21 | Cabometyx | $36 |
| Exelixis | Meals · 2025-06-21 | Cabometyx | $79 |
| Exelixis | Travel · 2025-06-21 | Cabometyx | $88 |
| Exelixis | Travel · 2025-06-21 | Cabometyx | $70 |
| Exelixis | Travel · 2025-06-21 | Cabometyx | $184 |
| Exelixis | Meals · 2025-06-21 | Cabometyx | $65 |
| Exelixis | Travel · 2025-06-21 | Cabometyx | $446 |
| Exelixis | Meals · 2025-06-20 | Cabometyx | $121 |
| Gilead Sciences | Meals · 2025-06-20 | Trodelvy | $21 |
| SpringWorks Therapeutics | Meals · 2025-06-18 | Ogsiveo | $35 |
| GlaxoSmithKline | Meals · 2025-05-30 | Ojjaara | $18 |
| Novartis Pharmaceuticals | Meals · 2025-05-29 | Pluvicto | $29 |
| Abbvie | Meals · 2025-05-28 | Elahere | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-23 | Enhertu | $16 |
| Iovance Biotherapeutics | Meals · 2025-05-15 | Amtagvi | $11 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-05-09 | Imfinzi | $1,675 |
| Exelixis | Meals · 2025-05-07 | Cabometyx | $22 |
| Exelixis | Meals · 2025-05-07 | Cabometyx | $1 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-04-25 | None | $1,675 |
| Celgene | Meals · 2025-04-21 | Opdivo | $24 |
| SpringWorks Therapeutics | Meals · 2025-04-09 | Ogsiveo | $27 |
| Abbvie | Meals · 2025-04-07 | Epkinly | $26 |
| Karyopharm Therapeutics | Meals · 2025-04-04 | Xpovio | $18 |
| Exelixis | Meals · 2025-03-24 | Cabometyx | $10 |
| Ipsen Biopharmaceuticals | Meals · 2025-03-20 | Onivyde | $26 |
| Novartis Pharmaceuticals | Meals · 2025-03-13 | Scemblix | $29 |
| Abbvie | Meals · 2025-02-28 | Epkinly | $21 |
| Cumberland Pharmaceuticals | Meals · 2025-02-25 | Sancuso | $21 |
| Lilly USA | Meals · 2025-02-24 | Verzenio | $16 |
| SpringWorks Therapeutics | Meals · 2025-02-13 | Ogsiveo | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-01 | Calquence | $21 |
| GlaxoSmithKline | Meals · 2025-01-28 | Jemperli | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-24 | Enhertu | $20 |
| Daiichi Sankyo | Meals · 2025-01-14 | Injectafer | $15 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-14 | Imfinzi | $65 |
| Celgene | Meals · 2025-01-13 | Opdualag | $15 |
| Merck Sharp & Dohme | Meals · 2025-01-10 | Welireg | $14 |
| Octapharma USA | Meals · 2025-01-10 | Octagam Immune Globulin (Human) | $45 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $7,587
| Gilead Sciences | Trodelvy | $3,373 | 9 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $2,613 | 6 payments
|
| Celgene | Reblozyl | $263 | 21 payments
|
| GlaxoSmithKline | Jemperli | $192 | 9 payments
|
| Abbvie | Elahere | $171 | 12 payments
|
| Exelixis | Cabometyx | $154 | 6 payments
|
| Daiichi Sankyo | Enhertu | $146 | 12 payments
|
| Novartis Pharmaceuticals | Pluvicto | $138 | 10 payments
|
| Seagen | None | $100 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $59 | 3 payments
|
| Ipsen Biopharmaceuticals | Onivyde | $55 | 2 payments
|
| Lilly USA | None | $54 | 1 payment
|
| BeiGene USA | Brukinsa | $36 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $34 | 2 payments
|
| PharmaEssentia USA | Besremi | $33 | 1 payment
|
| Sobi | Doptelet | $29 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Fruzaqla | $26 | 1 payment
|
| Eisai | Lenvima | $25 | 1 payment
|
| SpringWorks Therapeutics | Ogsiveo | $23 | 1 payment
|
| Sirtex Medical | Sir-Spheres Microspheres | $20 | 1 payment
|
| Pfizer | Lorbrena | $16 | 1 payment
|
| Servier Pharmaceuticals | None | $14 | 1 payment
|
| Agios Pharmaceuticals | Pyrukynd | $14 | 1 payment
|
2023: $7,380
| AstraZeneca Pharmaceuticals LP | Calquence | $5,101 | 9 payments
|
| Daiichi Sankyo | Enhertu | $814 | 4 payments
|
| Celgene | Opdualag | $258 | 22 payments
|
| Novartis Pharmaceuticals | Scemblix | $232 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $156 | 16 payments
|
| GlaxoSmithKline | Zejula | $148 | 7 payments
|
| Pharmacyclics LLC An AbbVie | Epkinly | $88 | 4 payments
|
| Regeneron Healthcare Solutions | Libtayo | $67 | 3 payments
|
| Ipsen Biopharmaceuticals | Tazverik | $45 | 2 payments
|
| Exelixis | Cabometyx | $44 | 2 payments
|
| Kite Pharma | None | $37 | 2 payments
|
| Janssen Biotech | Imbruvica | $34 | 2 payments
|
| Gilead Sciences | Trodelvy | $34 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $33 | 1 payment
|
| Pfizer | Ibrance | $32 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $31 | 1 payment
|
| AbbVie | Venclexta | $24 | 1 payment
|
| Incyte | Monjuvi | $22 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $21 | 1 payment
|
| Genzyme | Jevtana | $21 | 1 payment
|
| Genmab U.S. | Epkinly | $19 | 1 payment
|
| Stemline Therapeutics | Orserdu | $16 | 1 payment
|
| Lilly USA | Verzenio | $16 | 1 payment
|
| Pharmacosmos Therapeutics | Monoferric | $15 | 1 payment
|
| Apellis Pharmaceuticals | None | $15 | 1 payment
|
| Genentech USA | Tecentriq | $15 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $14 | 1 payment
|
| Sobi | Doptelet | $14 | 1 payment
|
| PharmaEssentia USA | Besremi | $14 | 1 payment
|
2022: $24,958
| Daiichi Sankyo | Enhertu | $21,276 | 12 payments
|
| Rigel Pharmaceuticals | Tavalisse | $1,170 | 1 payment
|
| Novartis Pharmaceuticals | Kisqali | $406 | 8 payments
|
| E.R. Squibb & Sons L.L.C. | Empliciti | $334 | 27 payments
|
| Celgene | Pomalyst | $314 | 23 payments
|
| Alexion Pharmaceuticals | Ultomiris | $239 | 3 payments
|
| Novocure GmbH | None | $200 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $191 | 8 payments
|
| GlaxoSmithKline | Zejula | $138 | 8 payments
|
| Amgen | Nplate | $112 | 6 payments
|
| Sobi | Doptelet | $101 | 5 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $70 | 3 payments
|
| Exelixis | Cabometyx | $52 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $45 | 3 payments
|
| G1 Therapeutics | Cosela | $44 | 2 payments
|
| Gilead Sciences | Trodelvy | $43 | 2 payments
|
| EMD Serono | None | $36 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $33 | 1 payment
|
| Kite Pharma | None | $31 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $30 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $22 | 1 payment
|
| Vertos Medical | Mild Device Kit | $21 | 1 payment
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $18 | 1 payment
|
| Janssen Biotech | None | $16 | 1 payment
|
| Heron Therapeutics | Sustol | $15 | 1 payment
|
2021: $8,440
| Karyopharm Therapeutics | Xpovio | $2,250 | 1 payment
|
| Daiichi Sankyo | Enhertu | $1,495 | 6 payments
|
| Epizyme | Tazverik | $1,268 | 2 payments
|
| Novartis Pharmaceuticals | Kisqali | $1,117 | 17 payments
|
| Seagen | Padcev | $1,014 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $186 | 25 payments
|
| GlaxoSmithKline | Zejula | $183 | 6 payments
|
| Incyte | Monjuvi | $139 | 2 payments
|
| Amgen | Xgeva | $135 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $81 | 4 payments
|
| BeiGene USA | Brukinsa | $67 | 3 payments
|
| Exelixis | Cabometyx | $62 | 4 payments
|
| Janssen Biotech | Darzalex | $54 | 3 payments
|
| Celgene | Reblozyl | $47 | 3 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $40 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $38 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $26 | 2 payments
|
| Genzyme | Elitek | $25 | 1 payment
|
| Myovant Sciences | Orgovyx | $24 | 1 payment
|
| MorphoSys US | Monjuvi | $20 | 1 payment
|
| Dova Pharmaceuticals | Doptelet | $17 | 1 payment
|
| Genentech USA | Kadcyla | $17 | 1 payment
|
| Kite Pharma | None | $15 | 1 payment
|
| Puma Biotechnology | Nerlynx | $15 | 1 payment
|
| Taiho Oncology | Inqovi | $15 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $14 | 1 payment
|
| Agios Pharmaceuticals | Tibsovo | $14 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $13 | 1 payment
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $13 | 1 payment
|
| Secura Bio | Farydak | $13 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $12 | 1 payment
|
| Gilead Sciences | None | $12 | 1 payment
|
2020: $3,186
| Celgene | None | $1,155 | 1 payment
|
| Eisai | Lenvima | $945 | 1 payment
|
| Daiichi Sankyo | Enhertu | $400 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $336 | 40 payments
|
| Astellas Pharma US | None | $65 | 1 payment
|
| Exelixis | Cabometyx | $52 | 3 payments
|
| Karyopharm Therapeutics | Xpovio | $41 | 2 payments
|
| Dova Pharmaceuticals | Doptelet | $39 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $36 | 2 payments
|
| Amgen | Kanjinti | $29 | 2 payments
|
| Novartis Pharmaceuticals | Mekinist | $24 | 2 payments
|
| GlaxoSmithKline | Blenrep | $24 | 1 payment
|
| AbbVie | Venclexta | $23 | 1 payment
|
| Janssen Biotech | Darzalex | $18 | 1 payment
|
2019: $3,354
| Genzyme | Elitek | $2,013 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $193 | 17 payments
|
| Cardinal Health 108 | None | $152 | 2 payments
|
| Sirtex Medical | Sir-Spheres Microspheres | $150 | 1 payment
|
| Kite Pharma | Yescarta | $118 | 1 payment
|
| Genentech USA | Perjeta | $114 | 14 payments
|
| Seattle Genetics | Adcetris | $93 | 3 payments
|
| Amgen | Nplate | $90 | 1 payment
|
| TerSera Therapeutics | Zoladex | $84 | 4 payments
|
| Novartis Pharmaceuticals | Tasigna | $76 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $34 | 2 payments
|
| Gilead Sciences | None | $30 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | None | $28 | 2 payments
|
| Janssen Biotech | Imbruvica | $26 | 2 payments
|
| EMD Serono | Bavencio | $21 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $17 | 1 payment
|
| Incyte | Jakafi | $16 | 1 payment
|
| Shire North American Group | Vonvendi | $16 | 1 payment
|
| Tesaro | Zejula | $15 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $15 | 1 payment
|
| Pfizer | Ibrance | $14 | 1 payment
|
| Kyowa Kirin | Poteligeo | $14 | 1 payment
|
| Dova Pharmaceuticals | Doptelet | $13 | 1 payment
|
| Exelixis | Cabometyx | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Genentech, Inc. · T Dm1 Atezolizumab in High Risk Her2 Patients With Residual Disease · 2022 | Their institution | $10,713 |
Professional record
- NPI
- 1700047180
- Licence
- CA 20A11638, MA 245774
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- Po Box 25100, Fresno, CA, 93729
- NPI first listed
- 2008-06-19
- NPI last updated
- 2025-10-09
- NPI record certified
- 2025-10-09
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1125 E Spruce Ave Ste 103, Fresno, CA, 93720